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Abstract
A stochastic Markov chain model for metastatic progression is developed for primary lung cancer based on a network
construction of metastatic sites with dynamics modeled as an ensemble of random walkers on the network. We calculate a
transition matrix, with entries (transition probabilities) interpreted as random variables, and use it to construct a circular bi-
directional network of primary and metastatic locations based on postmortem tissue analysis of 3827 autopsies on
untreated patients documenting all primary tumor locations and metastatic sites from this population. The resulting 50
potential metastatic sites are connected by directed edges with distributed weightings, where the site connections and
weightings are obtained by calculating the entries of an ensemble of transition matrices so that the steady-state distribution
obtained from the long-time limit of the Markov chain dynamical system corresponds to the ensemble metastatic
distribution obtained from the autopsy data set. We condition our search for a transition matrix on an initial distribution of
metastatic tumors obtained from the data set. Through an iterative numerical search procedure, we adjust the entries of a
sequence of approximations until a transition matrix with the correct steady-state is found (up to a numerical threshold).
Since this constrained linear optimization problem is underdetermined, we characterize the statistical variance of the
ensemble of transition matrices calculated using the means and variances of their singular value distributions as a
diagnostic tool. We interpret the ensemble averaged transition probabilities as (approximately) normally distributed
random variables. The model allows us to simulate and quantify disease progression pathways and timescales of
progression from the lung position to other sites and we highlight several key findings based on the model.
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Introduction
The identification of circulating tumor cells (CTCs) in the
human circulatory system dates back to Ashworth’s 1869 paper [1]
in which he identified and pointed out the potential significance of
cells similar to those found in the primary tumor of a deceased
cancer victim. Since then, there has been sporadic focus on CTCs
as a key diagnostic tool in the fight against cancer, based mostly on
the so-called ‘seed and soil’ hypothesis [2–4] of cancer metastasis,
in which the CTCs play the role of seeds which detach from the
primary tumor, disperse through the bloodstream, and get trapped
at various distant sites (typically small blood vessels of organ
tissues), then, if conditions are favorable, extravasate, form
metastases, and subsequently colonize. The metastatic sites offer
the soil for potential subsequent growth of secondary tumors.
Paget’s 1889 seed-and-soil hypothesis [3] asserts that the
development of secondary tumors is not due to chance alone,
but depends on detailed interactions, or cross-talk, between select
cancer cells and specific organ microenvironments. In 1929,
J. Ewing challenged the seed-and-soil hypothesis [5] by proposing
that metastatic dissemination occurs based on purely mechanical
factors resulting from the anatomical structure of the vascular
system, a proposal that is now known to be too simplistic an
explanation for the metastatic patterns that are produced over
large populations. While the seed-and-soil hypothesis remains a
bedrock theory in cancer research, it has been significantly refined
over the years to incorporate our current level of understanding on
how the ability for a tumor cell to mestastasize depends on its
complex interactions with the homeostatic factors that promote
tumor cell growth, cell survival, angiogenisis, invasion, and
metastastasis [2].
A schematic diagram associated with the metastatic process is
shown in Figure 1. Here, the primary tumor (from which the
CTCs detach) is located in the lower part of the diagram and the
distant potential secondary locations where CTCs get trapped and
form metastases are shown. In this paper, we will not be concerned
with extravasation, colonization and the formation of secondary
tumors which are complex processes in their own right [4], but
rather with a probabilistic description of metastatic progression
from primary neoplasm to metastatic sites; hence, we provide a
quantitative framework for charting the time-evolution of cancer
progression along with a stochastic description of the complex
interactions of these cells with the organ microenvironment. Also
shown in the figure are representative scales of a typical red blood
cell (8 mm), capillary diameter (5–8 mm), CTC (20 mm), and
human hair diameter (100 mm). The total number of remote sites
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is relatively small (see the autopsy data set described in [6]), say on
the order of 50 locations, those sites presumably being the
locations at which CTCs get trapped and subsequently colonize.
For any individual making up the ensemble, of course, the number
of sites with metastatic tumors would be much smaller. A ‘ballpark’
estimate, based on the ratio of mets to primaries (from [6]) suggests
a number around 9484/3827,2.5, although in the modern era,
this number is probably higher. A reasonably thorough overview
of this process is described in [7].
It wasn’t until recently, however, that important technological
developments in the ability to identify, isolate, extract, and
genetically and mechanically study CTCs from cancer patients
became available (see, for example [8–15]). These new approach-
es, in turn, produced the need to develop quantitative models
which can predict/track CTC dispersal and transport in the
circulatory and lymphatic systems of cancer patients for potential
diagnostic purposes. As a rough estimate, data (based primarily on
animal studies) shows that within 24 hours after release from the
primary tumor, less than 0.1% of CTCs are still viable, and fewer
than those, perhaps only a few from the primary tumor, can give
rise to a metastasis. There are, however, potentially hundreds of
thousands, millions, or billions of these cells detaching from the
primary tumor continually over time [16,17], and we currently do
not know how to deterministically predict which of these cells are
the future seeds, or where they will take root. All of these estimates,
along with our current lack of detailed understanding of the full
spectrum of the biological heterogeneity of cancer cells, point to
the utility of a statistical or probabilistic framework for charting the
progression of cancer metastasis. This is a particularly important
step for any potential future comprehensive computer simulation
of cancer progression, something not currently feasible. Although
Figure 1. Schematic diagram of human circulatory system showing circulating tumor cells (CTCs) detaching from primary tumor
and getting trapped in capillary beds and other potential future metastatic locations as outlined by the ‘seed-and-soil’ framework.
doi:10.1371/journal.pone.0034637.g001
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which the disease spreads, the probabilistic framework obviates the
need to model all of the biomechanical features of the complex
processes by which cells journey through the vascular/lymphatic
system. This paper provides the mathematical/computational
framework for such an approach.
In this paper, we develop a new Markov chain based model of
metastatic progression for primary lung cancer, which offers a
probabilistic description of the time-history of the disease as it
unfolds through the metastatic cascade [4]. The Markov chain is a
dynamical system whose state-vector is made up of all potential
metastatic locations identified in the data set described in [6]
(defined in Table 1), with normalized entries that can be
interpreted as the time-evolving (measured in discrete steps k)
probability of a metastasis developing at each of the sites in the
network. One of the strengths of such a statistical approach is that
we need not offer specific biomechanical, genetic, or biochemical
reasons for the spread from one site to another, those reasons
presumably will become available through more research on the
interactions between CTCs and their microenvironment. We
account for all such mechanisms by defining a transition
probability ( which is itself a random variable) of a random walker
dispersing from one site to another, thus creating a quantitative
and computational framework for the seed-and-soil hypothesis as
an ensemble based first step, then can be further refined primarily
by using larger, better, and more targeted databases such as ones
that focus on specific genotypes or phenotypes, or by more refined
modeling of the correlations between the trapping of a CTC at a
specific site, and the probability of secondary tumor growth at that
location.
The Markov chain dynamical system takes place on a metastatic
network based model of the disease, which we calculate based on
the available data over large populations of patients. In particular,
we use the data described in the autopsy analysis in [6] in which
metastatic distributions in a population of 3827 deceased cancer
victims were analyzed. None of the victims received chemotherapy
or radiation. The autopsies were performed between 1914 and
1943 at 5 separate affiliated centers, with an ensemble distribution
of 41 primary tumor types, and 30 metastatic locations. Figure 2
shows histograms of the number of metastases found at the various
sites in the population. Figure 2(a) shows the metastatic
distribution in the entire population, while Figure 2(b) shows the
distribution in the subset of the population with primary lung
cancer. We note that this data offers no particular information on
the time history of the disease for the population or for individual
patients - only the long-time metastatic distribution in a population
of patients, where long-time is associated with end of life, a
timescale that varies significantly from patient to patient (even
those with nominally the same disease). Although this paper
focuses on a model for primary lung cancer, the approach would
work equally well for all of the main tumor types. Indeed, one of
the goals of future studies will be to compare the models obtained
for different cancer types.
Network based models of disease progression have been
developed recently in various contexts such as the spread of
computer viruses [18], general human diseases [19], and even
cancer metastasis [20], but as far as we are aware, our Markov
chain/random walk approach to modeling the dynamics of the
disease on networks constructed for each primary cancer type
from patient populations offers a new and potentially promising
computational framework for simulating disease progression.
More general developments on the structure and dynamics on
networks can be found in the recent works [21–26]. For brief
introductions to some of the mathematical ideas developed in this
paper, see [27–30].
Results
In this section we describe three main results from the model.
First, the model separates the 27 non-zero sites from Figure 2(b)
into what we call ‘first-order’ sites (20 of these), and ‘second-order’
sites (7 of these). Second, the model quantifies the ability of each
site to self-seed by ranking the average edge weight of each site
back to itself (see [31]). Of these, the strongest self-seeders are the
lymph nodes, bone, kidney, and lung. Third, the model allows us
to calculate a time-ordering (model based) associated with
metastatic progression. This is achieved by performing Monte
Carlo simulations of the mean first-passage times from the lung site
to each of the other sites in the network. The mean first-passage
time is the average number of edges a random walker must
traverse in order to hit a given site, hence the number is not
restricted to take on discrete integer values. We think of these
mean first-passage times as the proxy timescale for progression. In
principle, they can be calculated analytically using the fundamen-
tal matrix (see [32]), but in practice, since this involves inverting
the 50650 transition matrix, it is far more convenient to obtain the
results numerically via Monte Carlo simulations. The results will
be described in terms of a ‘random walker’ leaving the lung site
Table 1. Metastatic site numbering system.
# Name # Name
1 Adrenal* 26 Omentum*
2 Anus 27 Ovaries
3 Appendix 28 Pancreas*
4 Bile Duct 29 Penis
5 Bladder 30 Pericardium*
6 Bone* 31 Peritoneum*
7 Brain* 32 Pharynx
8 Branchial Cyst 33 Pleura*
9 Breast 34 Prostate*
10 Cervix 35 Rectum
11 Colon 36 Retroperitoneum
12 Diaphragm* 37 Salivary
13 Duodenum 38 Skeletal Muscle*
14 Esophagus 39 Skin*
15 Eye 40 Small Intestine*
16 Gallbladder* 41 Spleen*
17 Heart* 42 Stomach*
18 Kidney* 43 Testes
19 Large Intestine* 44 Thyroid*
20 Larynx 45 Tongue
21 Lip* 46 Tonsil
22 Liver* 47 Unknown
23 Lung* 48 Uterus*
24 Lymph Nodes (reg)* 49 Vagina*
25 Lymph Nodes (dist)* 50 Vulva
Site numbering system used in transition matrix and network model. The
* indicates an entry in the target vector associated with lung cancer primary
from the data set of [6].
doi:10.1371/journal.pone.0034637.t001
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the outgoing edges available to it at the site it is leaving, choosing a
given edge with the probability corresponding to its weighting.
Description of the Markov Chain Model
With the stochastic transition matrix Af, we briefly describe the
basic features and interpretations of a Markov dynamical system
model which we write as:
~ v vkz1~~ v vkAf,( k~0,1,2,,,,) ð1Þ
The matrix Af is our transition matrix which is applied to a
state-vector~ v vk at each discrete time-step k to advance to step kz1:
Thus, it is easy to see that:
~ v vk~~ v v0Ak
f , ð2Þ
where ~ v v0 is the initial-state vector. The underlying dynamics
associated with disease progression is interpreted as a random walk
on the weighted directed network defined by the entries of the
transition matrix.
The State Vectors and Definition of the Steady-state
To interpret the meaning of the initial-state vector and the
transition matrix, one should think of the patient’s initial tumor
distribution in terms of probabilities, or ‘uncertanties’. Thus, an
initial-state vector with a 1 in the 23rd entry:
~ v v0~(0,0,0,0,0,0,0,:::,1,:::)
in our 50 node model indicates, with absolute certainty, that the
patient has a primary tumor located in the ‘lung’ (position 23). At
the other extreme, we may have an initial-state vector:
~ v v0~(1=50,1=50,1=50,1=50,1=50,1=50,:::)
which indicates that all locations of the initial tumor distribution
are equally likely. One interpretation of this is that we have no
information at all about where the primary tumor is located. A
third possibility is that we have some limited information about the
initial tumor distribution, but not completely certain information,
thus an initial-state vector:
~ v v0~(1=2,0,0,0,0,0,1=2,0,0,0,0,0,0,0,0,0,:::)
would indicate that we think it likely that there is a primary tumor
in the ‘adrenal’ (position 1), or ‘brain’ (position 7), but we are not
sure which.
Then, we can ask how this initial information propagates
forward in time as the disease progresses. To advance one-step
forward in time, we apply the transition matrix once to the initial-
state vector, thus:
~ v v1~~ v v0Af:
This gives us our new state-vector~ v v1 after step one. For the next
step, we apply the transition matrix again, this time to~ v v1:
~ v v2~~ v v1Af~~ v v0A2
f:
The dynamical system proceeds according to eqns (2) in a
manner consistent with the schematic diagram from Figure 1. As
described in the introduction, it is best to think of the entries of the
state-vector as probabilities for metastases developing at each of
the discrete sites in our model (and in the data set), thus for the
seed to take root in the soil. The entries of the state-vector ~ v vk
continually get redistributed in time, as measured in discrete steps
k, until they reach the target steady-state distribution. A different
interpretation of the entries of the state-vector at each discrete step
is that they reflect the ensemble statistical distribution of a collection of
agents executing a random walk across the network. We should
point out, however, that for the ensemble of random-walkers all
leaving from the lung site, the best way to measure the passage of
time is via mean first-passage times to each of the sites, which we
compute using Monte Carlo simulations. It is important to keep in
mind that since the transition matrix is constructed based on an
autopsy data set, there is no direct information available on time-
histories of progression, only tumor distribution at time of
death. A big advantage of using this data set is that we are able
to build a model based on the ‘natural’ progression of the disease
(i.e. untreated patients), whereas clinical data on time-histories of
progression for untreated patients do not exist, as far as we are
aware. Therefore, our challenge is to extract as much information
as we can using the autopsy data set [6], keeping in mind that time
should be interpreted only as the model timescale of progres-
sion. A next step would be to calibrate these model timescales with
separate data sets containing time progression information, not
something we consider in this paper.
Now comes a natural and important question. After long-times
(k large), is there some steady-state distribution that is achieved by
the model? Correspondingly, given a particular primary tumor,
what are long-term probabilistic distributions of possible metasta-
ses? We call this distribution vector~ v v(0)
?, and define it as:
~ v v(0)
?~limk??~ v v0Ak
f : ð3Þ
Notice that if a steady-state distribution is achieved, then for
sufficiently large k,~ v v
(0)
kz1*~ v v
(0)
k , and since
~ v v
(0)
kz1~~ v v
(0)
k Af, ð4Þ
this implies that
~ v v(0)
?~~ v v(0)
?Af: ð5Þ
Figure 2. Metastatic distributions from autopsy data set extracted from 3827 patients [6]. Y-axis in each graph represents a proportion
between 0 and 1. The sum of all the heights is 1. These are the two key probability distributions used to ‘train’ our lung cancer progression model.
(a) Overall metastatic distribution including all primaries. We call this distribution the ‘generic’ distribution as it includes all primary cancer types.;
(b) Distribution of metastases associated with primary lung cancer. We call this distribution the ‘target’ distribution that we label~ v vT:
doi:10.1371/journal.pone.0034637.g002
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~ v v(0)
?(Af{I)~0, ð6Þ
which means that~ v v(0)
? is a left-eigenvector of Af corresponding to
eigenvalue l~1. This is a crucial and practical observation that
allows us to calculate the steady-state distribution~ v v(0)
? directly from
the transition matrix. Since the rows of Af add to one, it always
has at least one eigenvalue that is 1, hence there is always at least
one steady-state distribution, but there may be more than one –
this depends in detail on the matrix structure, something the
eigenvalue distribution [40] can reveal.
The target distribution for lung cancer shown in Figure 2(b) and
labeled ~ v vT is not a steady-state for the matrix A0, i.e.
~ v vT(A0{I)~(~ v vT{~ v v(0)
?)(A0{I)=0, ð7Þ
since E~ v vT{~ v v(0)
?E
2=0:
Figure 3. The converged lung cancer network shown as a circular, bi-directional, weighted graph. We use sample mean values for all
edges connecting sites in the target distribution. The disease progresses from site 23 (lung) as a ‘random walker’ on this network. Arrow heads placed
on the end or ends of the edges denote the direction of the connections. Edge weightings are not shown. There are 50 sites (defined in Table 1)
obtained from the full data set of [6], with ‘Lung’ corresponding to site 23 placed on top. The 27 sites that are connected by edges are those from the
target vector for lung cancer defined in Table 1.
doi:10.1371/journal.pone.0034637.g003
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the Steady-state
Figure 3 shows the network diagram associated with the
ensemble averaged converged matrix - this is the lung cancer
network conditioned on our initial guess A0 averaged over 1000
training sessions. Each of the sites has incoming and outgoing
edges (denoted with arrow heads) which connect it to other sites in
the target distribution where the cancer can spread, and each of
the edges have a probabilistic weighting (not shown), with the
constraint that the weightings associated with all outgoing edges at
each site must sum to 1. The disease spreads across the network
from an initial site following a random walk. To minimize the
number of edges depicted in the figure, we have combined
incoming and outgoing edges whenever possible, and placed arrow
heads on both ends of an edge, instead of plotting the two edges
separately.
In Figure 4 we plot the (mean) edge weightings of the outgoing
edges from the lung, as compared with the values of the target
distribution shown in Figure 2(b). The differences show that the
values in the lung row of Af have adjusted from their initial values
in A0: Figure 5 and Figure 6 highlight our interpretation of the
transition probabilities, or edge values of the network, as random
variables. We show in these figures the distributions associated
with the ensemble of lung to regional lymph node (Figure 5) edge
values, and those associated with the lung to adrenal (Figure 6)
edge values. In each case, we histogram the edge values from the
1000 converged matrices, and use the sample means and variances
to overlay a corresponding normal distribution. The vertical
dashed lines in Figures 5 and 6 show the initial value of the
transition probability from lung to regional lymph nodes (Figure 5)
and lung to adrenal (Figure 6). These initial values used in the
matrix A0 are obtained using the entire data set of DiSibio and
French [6], i.e. over all primary cancer types. The converged
Gaussian distributions shown in these figures, however, are specific
to lung cancer only. The fact that the mean is clearly shifted to the
left of the vertical line in Figure 5 indicates that the lung to
regional lymph node connection for lung cancer is less significant,
statistically, than for other cancer types. A possible anatomical
explanation for this left shift could be the fact that regional lymph
nodes, for lung cancer, are located very close to the lung itself,
compared with their typical distance away from other primary
tumor locations. Because of this unusually close proximity,
regional lymph nodes could easily have been mistakingly
considered as part of the lung in some of the autopsies in the
series, effectively reducing the significance of the lung to regional
lymph node connection. By contrast, the right shift of the mean,
shown in Figure 6 for the lung to adrenal connection, would
indicate that the lung to adrenal connection is statistically more
important for lung cancer than for other primary cancer types.
This could be due to the documented anatomic connection
between lung and adrenal that is known, but has not, to date, been
a particular focus of lung cancer metastasis studies.
The dynamical system defined by the Markov process:
~ v vkz1~~ v vkAf,( k~0,1,2,,,,) ð8Þ
Figure 4. Weight of outgoing edges from the lung (using sample mean values from ensemble) as compared with the ‘target’
distribution.
doi:10.1371/journal.pone.0034637.g004
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associated with random walkers traversing the network. Figures 7
and 8 show the dynamical progression of the initial state vector,
starting with an initial state-vector corresponding to a lung tumor,
i.e. 1 in position 23, with 0’s elsewhere. In the sequence, the target
vector ~ v vT is depicted with filled bars, while the vector ~ v vk (for
k~0,2,5,?) is depicted with unfilled bars. Convergence to the
target is exponential. By k=5, convergence to the steady-state is
essentially complete.
First and Second Order Sites
The 27 metastatic sites associated with lung cancer shown in the
distribution of Figure 2(b) can be separated into two distinct
groups in light of the ensemble averaged transition probabilities
listed in decreasing order in Table 2. The middle column of this
table shows the transition probability going directly from the lung
to each of the 27 sites of the target vector (ensemble
averaged6standard deviations). The right column of the table
shows the most likely two-step path from lung to each of the sites
listed on the left, via the most probable intermediate site. Thus it
shows the product of the direct transition probability from lung to
an intermediate site (in parentheses on right), times the transition
probability from that intermediate site to the site listed on the left.
When one compares these values (all are ensemble averaged) it is
clear that the top 20 sites (listed above the cut-off line) have direct
transition values higher than their most probable two-step
transition, hence we call these ‘first-order’ sites. If the disease
reaches one of these sites, the most likely path is directly from the
lung after one-step. A random walker, leaving the lung site, after it
chooses one of the available outgoing edges with probability
corresponding to the edge weighting, will first visit one of these
first-order sites. The most heavily weighted edges, hence the most
likely first site visits, will be lymph nodes (reg) and adrenal,
accounting for roughly 28% of the first-site visits. The next two
most heavily weighted sites are lymph nodes (dist) and liver. These
four sites account for roughly 50% of the first site visits of an
ensemble of random walkers.
The remaining 7 sites (below the cut-off, starting from skin) have
two-step transition path probabilities that are equal to or more
probable than their direct one-step path from lung (taking into
account standard deviations). We call these the ‘second-order’
sites. The interpretation of these sites is if there is a metastatic
tumor at one of these sites, it is equally probable, or more probable
that there is also a metastatic tumor at an intermediate site, most
probably the lymph nodes (reg) or adrenal gland. Skin is the most
significant second-order site, suggesting a possible pathway from a
primary tumor in the lung to a metastatic tumor on the skin via the
Figure 5. Histogram of edge values from lung to lymph nodes (reg) for 1000 trained Af ’s, showing that edge values (transition
probabilities) are best thought of as random variables which are (approximately) normally distributed. Dashed vertical line shows
initial edge value associated with A0: Normal distribution with sample mean (0.15115) and variance (0.01821) is shown as overlay.
doi:10.1371/journal.pone.0034637.g005
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probable).
The classification of sites allows us to quantify possible disease
progression paths (described in terms of ‘random-walkers’) from
lung to a given metastatic location. This is shown in Figure 9
where we focus on the multiple pathways by which cancer can
spread from a primary lung tumor to the liver. We show in the
figure the outgoing connection from lung to liver (with weight
0.0802860.00946), since liver is a first-order site. Roughly 92% of
the random walkers, however, do not transition to liver on the first
step, but go instead to a different first-order site. Some of these will
pass to the liver on the second step, as shown by the directed (solid)
arrows. Still others pass to a second-order site, and then to the
liver, as shown by the directed (dashed) arrows. In this way, all
possible pathways to the liver from lung can be compared
probabilistically and one can make quantitative predictions on
which other sites might have metastases if a lung cancer patient
develops a metastatic liver tumor.
Self-seeding Sites
A recent focus in the literature has been on the possibility that
tumors can ‘self-seed’ (see [31,33]) since that process would help
explain the exceptionally rapid (‘Gompetzian’ [34]) growth of
certain primary tumors. In addition, these papers discuss the
possibility, not yet proven experimentally, that self-seeding could
potentially occur from a metastatic site back to itself, i.e.
‘metastasis re-seeding’. The focus on self-seeding of the primary
tumor (circulating tumor cells that colonize their tumors of origin)
demonstrated convincingly in mouse models [33] has led to the
general concept that cancer progression, and hence progression
pathways, may not be a strictly uni-directional process of
progression from primary tumor to sequentially distant metastatic
sites. It may well involve aspects that are more multi-directional in
nature, such as tumor self-seeding, re-seeding of the primary
tumor from a metastatic tumor, or re-seeding of a metastatic site
from the metastatic tumor. Experimental evidence and the
development of theoretical models that support this, is currently
an active area of research. In our model, a site that is self-seeding is
one in which a random-walker leaving that site can return directly.
The simplest way (but not the only way) to do this would be after
one step, if the site has an edge connecting back to itself. This
would correspond to a non-zero probability in the diagonal entry
of the transition matrix. We list in Table 3 the sites that have this
property, along with the edge weighting, listed from strongest to
weakest. For primary lung cancer, the most strongly weighted self-
connecting edges are the lymph nodes (reg and dist), liver, adrenal,
bone, and lung. A more thorough analysis of this potentially
important multi-directional mechanism of progression for each
Figure 6. Histogram of edge values from lung to adrenal for 1000 trained Af ’s showing that edge values (transition probabilities)
are best thought of as random variables which are (approximately) normally distributed. Dashed vertical line shows initial edge value
associated with A0: Normal distribution with sample mean (0.13165) and variance (0.01953) is shown as overlay.
doi:10.1371/journal.pone.0034637.g006
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Filled rectangles show the long-time metastatic distribution from the autopsy data in Figure 2(b), unfilled rectangles show the distribution at step k
using the Markov chain model. (a) k=0; (b) k=2.
doi:10.1371/journal.pone.0034637.g007
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Filled rectangles show the long-time metastatic distribution from the autopsy data in Figure 2(b), unfilled rectangles show the distribution at step k
using the Markov chain model. (a) k=5; (b) k=‘.
doi:10.1371/journal.pone.0034637.g008
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to self-seed will be the topic of a separate publication.
Mean First-passage Times
An important quantity associated with our model is called
‘mean first-passage time’ to each of the sites – how many steps, on
average, does it take for a random walker to pass from the lung site
to each of the other sites. This gives us a model based timescale
(not limited to take on discrete values) associated with disease
progression, something a static autopsy data set cannot give us
directly. It is important to keep in mind that these values are model
based only, they do not arise from comparisons of disease time
histories, something that could be done with a different data set
that contains time progression information. To calculate these
times, we follow a random walker starting at the lung position,
progressing from site to site until all of the sites have been visited at
least one time. Using this method for roughly 10,000 of these
random walkers, we collect statistical information on the mean
first-passage time to each of the sites, i.e. the average number of
steps it takes to first arrive at each site. We show below in Table 4
the mean first-passage times from the lung site, which we obtain by
Monte Carlo simulations using an ensemble of 10,000 realizations,
where each realization is run long enough in time so that all sites
identified by the lung cancer target vector are visited at least once.
We emphasize that the mean first-passage times are distributed
over a range of positive values quite distinct from the discrete
values required in the underlying Markov process.
Despite the fact that these mean first-passage times are model-
based (i.e. time passage information is not directly in the data set)
they are interesting from several points of view. The normalized
values, shown in the right column of the table, are obtained by
dividing each entry of the un-normalized column by the lymph
node (reg) passage time time of 5.6414. This way, everything is
measured with respect to the time associated with the progression
from lung to regional lymph nodes, providing a relative predictive
timescale for average progression. If a patient with a primary lung
tumor progresses to a metastatic tumor in the regional lymph
nodes after one year, one might expect it to take roughly another 6
months to progress to the distant lymph nodes, or roughly 9
months to the adrenal gland. The interpretation is not that the
disease will spread from lung to lymph nodes to liver to adrenal,
etc. all in one individual patient (since the model is based on an
ensemble data set), but that one, or perhaps several of these
secondary sites will eventually produce metastatic tumors, and we
have a predictive handle on the progression timescales. The mean
first-passage time histogram is plotted in Figure 10 and gives a
visual representation of the relative timescales to each of the sites.
The sites seem to be grouped into approximately three clusters. In
the first group, consisting of sites LN (reg) - Bone, there is an
approximate linear increase in the mean first-passage times. The
second grouping (Kidney - Peritoneum) also increases linearly, but
on a slightly shifted line. The third grouping (Large intestine -
Uterus) increases (roughly) exponentially. Sites in this group, with
very large mean first-passage times, like prostate or bladder, would
be ones in which, if a metastatic tumor does appear, would
indicate poor prognosis as other areas would have had a lot of time
and ‘probabilistic’ opportunities to develop tumors as well.
Not shown in the table and figure are mean first-passage times
from sites other than lung. But it is worth pointing out that we
have calculated these times starting at all 50 sites, and the shortest
mean first passage time occurs from pleura to adrenal, with a un-
normalized time of 1.02, or normalized value of 0.1811. This
exceptionally short passage time indicates that if the lung tumor
does progress to the pleura, one might expect a short time later for
progression to occur to the adrenal gland. As mentioned earlier,
this is another possible indication of the potential importance of
adrenal gland involvement in lung cancer progression. We are
currently comparing our model based mean first-passage times
with other data sets that contain the time-history of the disease in
individual patients and ensembles.
Discussion
The computational model we develop and discuss in this paper
is an ensemble based Markov chain/random walk model of
disease progression in which we use a stochastic transition matrix
with entries that are (approximately) normally distributed. The
model can help us quantify pathways of progression for lung
cancer, and can be used as a baseline model in which to compare
more targeted models which use correlations among sites making
up the ensemble (i.e. the individual patients making up the
Table 2. One and two-step transition probabilities.
Target Sites
One-step transition
prob (Avg)
Two-step transition
probs
Lymph Nodes (reg) 0.1511560.01821 0.02819 (LN (reg))
Adrenal 0.1316560.01953 0.01397 (LN (reg))
Lymph Nodes
(dist)
0.1192860.00279 0.01860 (LN (reg))
Liver 0.0802860.00946 0.01440 (LN (reg))
Kidney 0.0667760.01231 0.00709 (LN (reg))
Bone 0.0591460.00196 0.00931 (LN (reg))
Lung 0.0522360.01504 0.01214 (LN (reg))
Pleura 0.0473560.00338 0.00657 (LN (reg))
Pancreas 0.0466060.00785 0.00549 (LN (reg))
Heart 0.0363960.00739 0.00407 (LN (reg))
Spleen 0.0341560.00454 0.00432 (LN (reg))
Brain 0.0327460.00728 0.00360 (LN (reg))
Thyroid 0.0318060.00628 0.00356 (LN (reg))
Pericardium 0.0273360.00557 0.00306 (LN (reg))
Diaphragm 0.0216960.00216 0.00289 (LN (reg))
Large Intestine 0.0172460.00266 0.00219 (LN (reg))
Gallbladder 0.0101560.00048 0.00145 (LN (reg))
Stomach 0.0094960.00139 0.00119 (LN (reg))
Small Intestine 0.0078660.00158 0.00149 (LN (reg))
Skeletal Muscle 0.0041360.00093 0.00047 (LN (reg))
Skin 0.0043960.00443 0.00203 (LN (reg))
Peritoneum 0.0038460.00567 0.00308 (LN (reg))
Omentum 0.0030560.00223 0.00103 (LN (reg))
Prostate 0.0006460.00060 0.00025 (LN (reg))
Vagina 0.0005260.00059 0.00025 (LN (reg))
Bladder 0.0000960.00029 0.00023 (Adrenal)
Uterus 0.0000760.00025 0.00022 (Adrenal)
The 27 target sites listed in decreasing order of their edge weights (ensemble
average values) from lung site. The 20 sites above the ‘cut-off’ are called ‘First-
Order’ sites. Their direct connections from the lung are strong enough so that
they represent the most likely route to that site. The 7 sites listed below are
called ‘Second-Order’ sites. Their connections from the lung are sufficiently
weak that it is equally or more likely (taking into account standard deviations)
to get to the site via some other first-order site (shown in parentheses).
doi:10.1371/journal.pone.0034637.t002
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The model underscores the importance of the complex and
heterogeneous nature of the connections among the many
potential metastatic locations and bolsters the case for a fairly
complex view of the importance of a whole host of subtle
connections among sites that may or may not produce clinically
detectable tumors, but that seem crucial in the eventual detailed
understanding of cancer progression. We believe this autopsy
based ensemble study gives important baseline quantitative insight
into the structure of lung cancer progression networks that will be
useful for future comparisons. Similar techniques can be used for
other primary cancer networks. Three key findings based on the
model are:
(i) Metastatic sites can be classified into ‘first-order’ and
‘second-order’ sites based on the comparative values of the
one-step vs. two-step transition probabilities. This allows us
to lay out the layers of progression from lung to a given site,
such as liver, shown in Figure 9 which lays the groundwork
for a complete probabilistic classification of all pathways
from primary tumor sites to metastatic locations;
(ii) The classification and quantification of ‘self-seeding’ transi-
tion values gives us a network based interpretation of some
recent biological insights [33] that will be the focus of a
separate study on probabilistic mechanisms of multi-
directionality;
(iii) Model based mean first-passage times give us relative time
information (based on average passage time to regional
lymph nodes) about progression that can be used for future
comparisons with data sets that contain time progression
histories.
An important current direction of this work is to develop ‘data
assimilation’ tools that would allow us to incorporate new data
(non-autopsy data, individual patient histories, data made up of
patients with targeted treatments, etc.) into the ensemble model.
The problem is similar to that encountered by the weather
Figure 9. Probabilistic decomposition of pathways from lung to liver. First transition probability is directly from lung to liver
(0.0802860.00946). Paths from the first-order sites to liver are shown as solid arrows. Paths from second-order sites to liver are shown as dashed
arrows.
doi:10.1371/journal.pone.0034637.g009
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highly developed and have played a crucial role in going from
generic model-based calculations to targeted and accurate short
term calculations that focus on prediction and quantifying the
uncertainty inherent to the predictions [36].
Methods
Because we are computing the entries of a 50650 matrix using
only the 50 entries of our target steady-state, the solution to this
problem is not unique, a problem which is addressed in the works
of [37], [38], and [39] for example. In those papers, the solution to
this constrained linear inverse problem is obtained by identifying
the transition matrix that satisfies a certain maximum entropy
condition, and also one obtained by satisfying a least-squares
condition. More relevant to our problem is a criterion which
targets a family of solutions by pre-conditioning the search on an
approximate transition matrix informed by the data, followed by
an iteration process which then adjusts the entries until a transition
matrix with the correct steady-state is obtained. We show that this
process converges, and we use the algorithm to create an ensemble
of transition matrices whose entries are best interpreted as
(approximately) normally distributed random variables. We then
characterize the ensemble of stochastic transition matrices using
the means and variances of the singular value distributions [40]
associated with the ensemble.
Algorithm to Compute the Markov Transition Matrix
The three key steps in computing the transition matrix are:
(i) Step 1 - The choice of initial matrix A0:F i r s t ,a n
approximate transition matrix, A0, is obtained based on
information we extract directly from the data set [6]. For the
‘lung row’ of A0, we use the lung target distribution shown
in Figure 2(b), which is the metastatic distribution in a
population of people with lung cancer primary tumors. This
is our first approximation to how the outgoing edges from
the lung are weighted. On all of the other 49 rows, we use
the generic distribution shown in Figure 2(a). Since we do
not know, a priori, how any of the other metastatic sites
communicate with any of the others, we use this ‘agnostic’
distribution for all of these non-lung rows. Two key
properties of A0 constructed this way are that it has
Rank=2 (i.e. only two linearly independent rows), and it
does not have our target distribution shown in Figure 2(b) as
a steady-state, hence we know A0 is not the correct
Table 3. Self-edge weightings for each site.
Target Sites Self-edge weight (avg)
Lymph Nodes (reg) 0.186560.0152
Lymph Nodes (dist) 0.123160.0028
Liver 0.094560.0094
Adrenal 0.092960.0212
Bone 0.061660.0019
Lung 0.052260.0150
Kidney 0.047060.0143
Pleura 0.043460.0049
Pancreas 0.036060.0097
Spleen 0.028660.0057
Heart 0.026260.0088
Thyroid 0.023360.0076
Brain 0.023060.0092
Peritoneum 0.021160.0122
Pericardium 0.020360.0071
Diaphragm 0.019260.0031
Large Intestine 0.014160.0033
Skin 0.014060.0071
Small Intestine 0.009860.0019
Gallbladder 0.009760.0007
Stomach 0.008160.0019
Omentum 0.006860.0030
Skeletal Muscle 0.003260.0013
Bladder 0.002060.0025
Uterus 0.002060.0025
Vagina 0.001760.0012
Prostate 0.001760.0009
27 target sites and their self edge weights (ensemble average) listed in
decreasing order.
doi:10.1371/journal.pone.0034637.t003
Table 4. Mean first-passage times from lung.
Target Sites MFPT (unnormalized) MFPT (normalized)
Lymph Nodes (reg) 5.641460.4919 1.000060.0872
Lymph Nodes (dist) 8.354160.8096 1.480960.1435
Adrenal 10.034961.0068 1.778860.1785
Liver 10.613961.0226 1.881460.1813
Lung 13.028461.1497 2.309460.2038
Bone 16.027761.4508 2.841160.2572
Kidney 20.394461.9664 3.615160.3486
Pleura 22.932962.4375 4.065160.4321
Pancreas 26.435062.6438 4.685960.4686
Spleen 33.700963.4925 5.973960.6191
Heart 36.551363.6359 6.479160.6445
Brain 40.554064.3179 7.188660.7654
Thyroid 41.324064.0700 7.325160.7215
Pericardium 46.859964.1645 8.306460.7382
Diaphragm 51.337265.6196 9.100160.9961
Peritoneum 51.955565.4518 9.209760.9664
Large Intestine 69.050167.3192 12.239961.2963
Skin 79.200668.4505 14.039261.4979
Gallbladder 104.9654610.0373 18.606361.7792
Small Intestine 105.872369.9567 18.767061.7649
Stomach 122.4070612.7034 21.698062.2518
Omentum 155.6364615.8049 27.588362.8016
Skeletal Muscle 313.7172630.6400 55.609865.4313
Bladder 620.7585663.7243 110.0362611.2958
Prostate 630.6260668.4618 111.7854612.1356
Vagina 630.8929664.6222 111.8327611.4550
Uterus 633.1578663.9966 112.2342611.3441
Mean first-passage times (unnormailzed and normalized) from lung to each
target site, obtained by Monte Carlo simulation. Histogram plot is shown in
Figure 12.
doi:10.1371/journal.pone.0034637.t004
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iteration process in Step 2 which adjusts the entries of A0 to
arrive at a final transition matrix Af that has higher rank
(typically the same rank as the number of entries in the
target vector), and has the target distribution (Figure 2(b)) as
a steady-state.
(ii) Step 2 - The iteration process to Af : A0, is then used to start
an iteration process where the entries are adjusted
iteratively, using randomized adjustments, until its steady-
state distribution converges to the target distribution. The
converged matrix obtained after this process is what we call
the ‘trained’ lung cancer matrix, Af. We will discuss this key
step further below.
(iii) Step 3 - Creating an ensemble of Af’s: Because the iterative
procedure is based on random adjustments of the matrix
entries, and because we adjust the entries only up to some
pre-determined numerical value defined as our convergence
threshold (typically chosen to be O(10{5)), the transition
matrices produced from Step 2 should be thought of as
having entries that have some inherent probability distribu-
tion associated with them, with a sample mean and variance
obtained by collecting an ensemble of these matrices. We
will show two of the key edge probability distributions (lung
to regional lymph nodes, and lung to adrenal) and also
discuss the statistical spread of the ensemble of transition
matrices using their singular value distributions as a
diagnostic tool.
Convergence of the Algorithm
We now describe Step 2 of our algorithm in more detail, the
iterative training stage which takes us from our initial matrix A0,t o
our final matrix Af: Define the transition matrix after step j in the
iteration process to be Aj, with corresponding steady-state v(j)
?
defined as
~ v v(j)
?(Aj{I)~0: ð9Þ
Our goal is to find the entries of Aj so that
~ v vT(Aj{I)~0, ð10Þ
i.e. so that E~ v v(j)
?{~ v vTE
2~0. We do this iteratively as follows. Since
~ v vT=~ v v(j)
?, we can define a ‘residual’ at step j:
~ v vT(Aj{I)~~ r rj:(~ v vT{~ v v(j)
?)(Aj{I), ð11Þ
where E~ r rjE
2=0: Our goal is to find the entries of Aj so that
E~ r rjE
2ƒE%1 where e is defined as our numerical convergence
threshold. In practice, we do this by calculating E~ v vT{~ v v(j)
?E
2
directly and iterate the entries of Aj until E~ v vT{~ v v(j)
?E
2vE, where
typically we take E~O 10{5   
.
Stated more generally, our goal is to solve the following linear
constrained optimization problem. Given a target vector ~ v vT, find
Figure 10. Mean first-passage time histogram for Monte Carlo computed random walks all starting from lung. Error bars show one
standard deviation. Values are normalized so that lymph node (reg) has value 1, and all others are in these relative time units.
doi:10.1371/journal.pone.0034637.g010
Lung Cancer Progression via a Random Walk Model
PLoS ONE | www.plosone.org 15 April 2012 | Volume 7 | Issue 4 | e34637the entries aij of the matrix A to minimize the Euclidean norm of
the residual vector~ r r, where:
~ v vT(A{I)~~ r r: ð12Þ
The constraints are 0ƒaijƒ1, and
P50
j~1 aij~1: Most
importantly, we have pre-conditioned the iterative process in Step
1 on our particular initial matrix A0: The general framing of this
problem as a constrained optimization problem is discussed in
[37–39].
To do this, we iteratively adjust the entries of Aj at each step (so
as to maintain the constraint that all rows sum to one) according to
the following algorithm:
1. Calculate the residual~ r rj at step j, starting with A0, (j=0);
2. Pick the column of Aj corresponding to the maximum entry of
~ r rj;
3. Pick the column of Aj corresponding to the minimum entry of
~ r rj;
4. Pick a row of Aj at random;
5. Decrease the entry of Aj selected in step (ii) by d, increase the
entry of Aj selected in step (iii) by d, where d is scaled with the
size of E~ r rjE
2: This new matrix is Ajz1;
6. Calculate the new E~ r rjz1E
2 and stop if E~ r rjz1E
2vE: Otherwise
go to step (ii) and repeat the process.
Because of the randomized nature of the algorithm, and
because of the finite threshold of convergence, the converged final
matrix Af will be slightly different each time the iterative process is
carried out, even when all the trained matrices start with the same
initial A0. Thus, we carry out the iteration and convergence
process, producing an ensemble of 1000 final transition matrices
Af, and we show the convergence (down to O(10{5)) of the
ensemble in Figure 11 (plotted on a semi-log plot). The solid curve
is the average convergence rate computed from the 1000 training
sessions, while the error bars show the standard deviations
associated with the ensemble, showing the spread of the
convergence rates, which are relatively tight.
Figure 11. Ensemble convergence to Af, starting from A0. y-axis is E~ r rjE
2z, x-axis is step j. We use an ensemble of 1000 trained matrices Af,
each conditioned on the same initial matrix A0: The average convergence curve is shown, along with standard deviations marked along each decade
showing the spread associated with the convergence rates.
doi:10.1371/journal.pone.0034637.g011
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A very useful diagnostic tool to characterize the structure and
understand the statistical spread associated with the matrices in
the ensemble are the singular values, (ln (l1wl2w:::wl27w0),
associated with the collection of Af’s. These are shown in
Figure 12, plotted from largest to smallest. Values shown (as open
circles) are the sample means associated with the singular values of
the ensemble of 1000 converged matrices Af, all trained using the
same initial matrix A0: The error bars show the sample standard
deviations, which are small. The 27 non-zero singular values
reflect the fact that there are 27 entries in the steady-state
distribution for primary lung cancer. An equivalent way to say this
is that the rank of Af is 27, while the nullspace dimension is
(approximately) 23. The standard deviations show the statistical
spread associated with two sources of uncertainty, one is the
random search algorithm we use to obtain convergence, and the
other is the convergence threshold, which we typically take to be
O(10{5): The small standard deviations indicate that the
algorithm is converging to the same final Af, within a relatively
small range of statistical spread. On this graph, we also show the
least squares curve fit to singular values l4 through l24, which
follow a slope b*{0:1389, indicating that the singular values
roughly decrease like ln*aexp({bn)( a*0:1901): The two
diamond shaped data points on the graph correspond to the two
singular values of A0 reflecting the linear independence of the two
distributions from Figure 2 that we use in A0. We point out that
the Af’s should not be viewed as small perturbations of A0 - our
convergence algorithm starts with a rank 2 matrix and generates
an ensemble of (approximately) rank 27 matrices all within a
relatively tight statistical spread.
We also show one other set of singular values on the graph with
the asterix data points. To test the robustness of the ensemble with
respect to perturbations of the initial matrix A0, we start the search
with an initial matrix of the form A0zEA1: Here, the perturbation
matrix A1 is a 50650 rank 2 matrix obtained by giving each entry
in the lung row a uniformly distributed random number in the
Figure 12. Average distribution of the 27 non-zero singular values associated with the ensemble of 1000 matrices Af all obtained
using the same A0. x-axis is the index n, y-axis is ln. Data points (open circles) indicate the sample average, with error bars showing the sample
standard deviations. Line is a least squares curve fit through l4 through l24, showing linear decrease with exponent b~{0:1389: The 27 non-zero
singular values reflect the fact that there are 27 entries in the steady-state target distribution for primary lung cancer. The two diamond shaped data
points are the two singular values associated with the initial matrix A0: The 27 ‘asterix’ data points are those obtained from a trained matrix using a
perturbed A0, with Rank 2 perturbation. See text for details.
doi:10.1371/journal.pone.0034637.g012
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uniformly distributed random number in the interval [–1,1]. This
creates a random rank 2 matrix. The perturbation parameter E is
chosen so that the perturbation size is (roughly) 5% as compared
with the average row value of A0. The asterix data points, which
correspond to a converged Af below a threshold of O(10{10), all
fall within the one standard deviation bars of the unperturbed
values, again showing that the final converged matrix is relatively
robust to small changes in the initial matrix A0: For definiteness,
when we make conclusions associated with Monte Carlo
simulations, we use the ensemble averaged set of Af’s obtained
over a set of 1000 converged matrices, each converged to within
O(10{5): Because of this, we view the transition probabilities of
the Markov chain, i.e. the edge values in our network, as
themselves being random variables, with a standard deviation that
we can characterize.
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